ArticleCureus2025
A Case of Multicentric Isocitrate Dehydrogenase-Wildtype Glioblastoma With Divergent Clonal Evolution.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Here, we present a rare case of multicentric glioblastoma in which two spatially distinct tumors exhibited different molecular profiles. A 56-year-old woman presented with progressive headache and speech difficulties. Magnetic resonance imaging (MRI) of the brain revealed two separate contrast-enhancing lesions, one in the left superior temporal gyrus and the other in the right middle temporal gyrus, with no connecting tract or edema on fluid-attenuated inversion recovery (FLAIR) imaging. Multicentric glioblastoma was suspected, and the patient underwent two-stage surgical resection of both tumors to achieve gross total removal. Histopathology confirmed both lesions as isocitrate dehydrogenase (IDH)-wildtype glioblastoma (World Health Organization (WHO) Grade 4), with typical features including extensive necrosis and microvascular proliferation. However, targeted next-generation sequencing revealed distinct genetic alterations in the two tumors. The left temporal lobe lesion harbored TERT promoter (TERTp) and BRAF p.Val600Glu (V600E) mutations. In contrast, the right temporal lobe lesion harbored a TERTp mutation, epidermal growth factor receptor (EGFR) amplification, MDM4 amplification, and a homozygous deletion of CDKN2A/B. The patient underwent standard postoperative chemoradiotherapy. One year after surgery, the right tumor recurred, whereas no recurrence was observed in the left temporal lobe. The BRAF p.Val600Glu (V600E) mutation in the left-sided tumor is a potential target for molecular therapy and may have contributed to the lack of recurrence. Multicentric glioblastomas are extremely rare, and only a few cases have been genetically profiled to date. Notably, most reported multicentric glioblastomas exhibit monoclonal driver mutations across lesions, suggesting a single origin. In the present case, the two tumors had different molecular signatures. This case underscores the importance of comprehensive genetic analysis of multicentric glioblastomas and highlights how divergent molecular pathologies can inform the prognosis and open opportunities for targeted treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.